PE20110946A1 - Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia - Google Patents

Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia

Info

Publication number
PE20110946A1
PE20110946A1 PE2011001062A PE2011001062A PE20110946A1 PE 20110946 A1 PE20110946 A1 PE 20110946A1 PE 2011001062 A PE2011001062 A PE 2011001062A PE 2011001062 A PE2011001062 A PE 2011001062A PE 20110946 A1 PE20110946 A1 PE 20110946A1
Authority
PE
Peru
Prior art keywords
thrombocytopenia
reduce
thyrofiban
piperidinyl
mortality associated
Prior art date
Application number
PE2011001062A
Other languages
English (en)
Inventor
Marco Valgimigli
Original Assignee
Iroko Cardio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42198725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110946(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iroko Cardio Llc filed Critical Iroko Cardio Llc
Publication of PE20110946A1 publication Critical patent/PE20110946A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA SAL FARMACEUTICAMENTE ACEPTABLE DE TIROFIBAN TAL COMO CLORHIDRATO DE TIROFIBAN (N-(BUTILSULFONIL)-O-[4-(4-PIPERIDINIL)BUTIL]-L-TIROSINA MONO CLORHIDRATO O 2-S-(n-BUTILSULFONILAMINO)-3[4-(PIPERIDINIL-4)BUTILOXIFENIL] CLORHIDRATO DE ACIDO PROPIONICO), DONDE DICHO PRINCIPIO ACTIVO INHIBE LA ACTIVIDAD PLAQUETARIA MEDIANTE EL BLOQUEO DEL RECEPTOR PLAQUETARIO GLICOPROTEINA IIb/IIIa Y ES UTIL EN LA REDUCCION DEL RIESGO DE TROMBOCITOPENIA
PE2011001062A 2008-11-21 2009-11-20 Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia PE20110946A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11697608P 2008-11-21 2008-11-21

Publications (1)

Publication Number Publication Date
PE20110946A1 true PE20110946A1 (es) 2012-01-05

Family

ID=42198725

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001062A PE20110946A1 (es) 2008-11-21 2009-11-20 Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia

Country Status (18)

Country Link
US (1) US20120059036A1 (es)
EP (1) EP2355824A4 (es)
KR (1) KR20110108330A (es)
AU (1) AU2009318101A1 (es)
BR (1) BRPI0920984A2 (es)
CL (1) CL2011001175A1 (es)
CO (1) CO6390039A2 (es)
CR (1) CR20110271A (es)
DO (1) DOP2011000149A (es)
EC (1) ECSP11011152A (es)
MA (1) MA32820B1 (es)
MX (1) MX2011005376A (es)
NI (1) NI201100101A (es)
PE (1) PE20110946A1 (es)
SV (1) SV2011003915A (es)
TN (1) TN2011000256A1 (es)
WO (1) WO2010059244A2 (es)
ZA (1) ZA201103741B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101996880B1 (ko) 2018-03-16 2019-07-05 경성대학교 산학협력단 컴파운드 k를 유효성분으로 포함하는 혈소판 감소증 예방 또는 치료용 조성물
CN112441962A (zh) * 2019-09-04 2021-03-05 武汉武药科技有限公司 替罗非班及其纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
HUP0303917A2 (hu) * 2001-01-26 2004-03-01 Schering Corporation Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
US6770660B2 (en) 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
KR20050057294A (ko) * 2002-09-09 2005-06-16 트라이젠 리미티드 보론산 염, 및 혈전증의 치료를 위한 그것의 용도
KR20070032648A (ko) * 2004-05-12 2007-03-22 브리스톨-마이어스 스큅 컴퍼니 혈전 상태의 치료에 유용한 ｐ２ｙ１ 수용체의 우레아길항제
AU2005296305A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease

Also Published As

Publication number Publication date
WO2010059244A3 (en) 2010-10-14
ZA201103741B (en) 2012-01-25
US20120059036A1 (en) 2012-03-08
EP2355824A4 (en) 2012-11-07
NI201100101A (es) 2011-12-19
CL2011001175A1 (es) 2011-11-11
TN2011000256A1 (en) 2012-12-17
BRPI0920984A2 (pt) 2017-07-11
AU2009318101A1 (en) 2010-05-27
KR20110108330A (ko) 2011-10-05
EP2355824A2 (en) 2011-08-17
MX2011005376A (es) 2011-10-19
DOP2011000149A (es) 2011-10-31
CR20110271A (es) 2011-10-13
MA32820B1 (fr) 2011-11-01
CO6390039A2 (es) 2012-02-29
SV2011003915A (es) 2011-07-01
WO2010059244A2 (en) 2010-05-27
ECSP11011152A (es) 2011-09-30

Similar Documents

Publication Publication Date Title
PE20141296A1 (es) Composiciones y metodos para tratar el virus de la hepatitis c
EA201490919A1 (ru) Производные бетулина
PE20160205A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
BR112014010576A8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
PE20141321A1 (es) Combinaciones de principios activos
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
NI201200017A (es) Formulación farmacéutica
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
BR112013022915A2 (pt) célula geneticamente modificada, vetor, processo de conversão de ácido 5-(hidroximetil) furan-2-carboxílico (ácido hmf), e uso de uma célula geneticamente modificada
CO6362006A2 (es) Agonistas de los receptores de la melanocortina
PE20120585A1 (es) Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofensil)-5-hidroximetil oxazolidin-2-ona
CL2015002402A1 (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenergico asi como actividad antagonista del receptor muscarínico m3.
HN2011001446A (es) Compuesto utiles para inhibir chk1
CR20160465A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
AR085856A1 (es) Formas cristalinas del acido (2s)-2-ter-butoxi-2-(4-(2,3-dihidropirano[4,3,2-de]quinolin-7-il)-2-metilquinolin-3-il)acetico
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CL2012000263A1 (es) Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.
BR112015011200A2 (pt) 6-((s)-1-{1-[5-(2-hidróxi-etóxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como um antagonista do receptor de ampa dependente de tarp-gama 8
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
PE20110946A1 (es) Metodo para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia
CO6361921A2 (es) 3-aminociclopentancarboxamidas
CL2013003651A1 (es) Uso de una composición que comprende un antagonista del receptor de quimiocina c-c tipo 5 (ccr5) para preparar un medicamento útil para tratar una infección por staphylococcus aureus, donde dicha infección por s. aureus es causada por una cepa de s. aureus que expresa luke/d.
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
FR2981089B1 (fr) Production d'isopropanol par des souches recombinantes ameliorees

Legal Events

Date Code Title Description
FC Refusal